Phase 1 SAD/MAD study of SBT-020 in Healthy Subjects
Latest Information Update: 17 Jul 2026
At a glance
- Drugs SBT 020 (Primary)
- Indications Huntington's disease
- Focus Adverse reactions
Most Recent Events
- 16 Jun 2026 According to Stealth BioTherapeutics media release, Stealth BioTherapeutics is now called Mighty Therapeutics.
- 09 Mar 2017 New trial record